Biophytis Valuation Multiples

Biophytis Overview

About Biophytis

Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.

Founded

2006

HQ

Employees

19

Website

biophytis.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($18M)

EV

$9M

Valuation Multiples

Multiples.vc

Start free trial

Biophytis Financials

Biophytis reported last 12-month revenue of $2M and negative EBITDA of ($18M).

In the same LTM period, Biophytis generated ($18M) in EBITDA losses and had net loss of ($22M).

Biophytis P&L

In the most recent fiscal year, Biophytis reported revenue of — and EBITDA of ($11M).

Biophytis expects next 12-month revenue of XXX and NTM EBITDA of XXX

Biophytis Stock Performance

Biophytis has current market cap of $2M, and enterprise value of $9M.

Biophytis' stock price is $0.02.

Biophytis Valuation Multiples

Biophytis trades at 4.5x EV/Revenue multiple, and (0.5x) EV/EBITDA.

Biophytis Financial Valuation Multiples

As of April 12, 2026, Biophytis has market cap of $2M and EV of $9M.

Equity research analysts estimate Biophytis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biophytis has a P/E ratio of (0.1x).

Biophytis Margins & Growth Rates

Biophytis' revenue in the last 12 month grew by 22%.

Biophytis' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

Biophytis' rule of 40 is (1202%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Biophytis' rule of X is (1154%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Biophytis Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Biophytis M&A Activity

Biophytis acquired XXX companies to date.

Last acquisition by Biophytis was on XXXXXXXX, XXXXX. Biophytis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Biophytis Investment Activity

Biophytis invested in XXX companies to date.

Biophytis made its latest investment on XXXXXXXX, XXXXX. Biophytis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).